Studies show that more than two-thirds of aesthetically-oriented consumers are bothered by submental fullness, or “double chin.” And with social media profile images becoming more important than ever, there is interest in looking one’s best.
Submental fullness due to fat beneath the chin can impact a broad range of both men and women and because the condition can be genetic and resistant to diet and exercise. But there’s KYBELLA®, the first and only FDA-approved injectable treatment that is available by prescription only, that has been proven to improve the appearance of moderate to severe fat beneath the chin by physically destroying fat cells in the treatment area. In two pivotal clinical studies for KYBELLA®, reductions in submental fat volume were observed more frequently in the KYBELLA® treated group of 514 patients compared to the placebo group (508 patients) as measured by both clinician and patient ratings. In addition, visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were evaluated using a 6-question survey and 79% of 1 and 2-grade composite responders reported satisfaction after 12 weeks post final treatment compared with 33.6% of patients who received placebo.
To view the multimedia release go to:
http://www.multivu.com/players/English/7962051-kybella-injectable-double-chin-treatment-campaign/
West Pharmaceutical Services, Inc. (NYSE: WST) and HealthPrize Technologies, LLC, today announced the completion of the first two phases of their four-phase strategic collaboration. The companies are working to integrate HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient-engagement platform with West’s injectable drug delivery systems to provide an end-to-end connected health solution for pharmaceutical companies and the patients they serve. The combined offering will provide voluntary, electronically connected drug delivery systems that track when patients take their medication. The HealthPrize system engages and educates patients to increase adherence and medical literacy, rewarding interaction and compliance with prescribed treatment plans, and contributing to better health outcomes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7625851-west-pharma-healthprize-tech-collaboration/
Ascensia Diabetes Care today announced the availability of the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) in the United Kingdom, one of the next steps in the evolution of self-monitoring of blood glucose. As part of the system, the CONTOUR®NEXT ONE meter and CONTOUR®DIABETES app seamlessly connect, which makes capturing blood glucose results effortless for people with diabetes. The system enables patterns and trends to be revealed that can help people understand their diabetes, and may help to improve diabetes management.
The system features an easy-to-use wireless-enabled smart meter that links to a smart mobile device via Bluetooth® connectivity. The CONTOUR®NEXT ONE meter gives immediate feedback and also seamlessly connects to the CONTOUR®DIABETES app, which collects, stores and analyses patient blood glucose results received from the meter. The app combines these results with other data recorded by the user, to provide detailed information about their condition that can help them understand how their everyday lives may impact their blood glucose readings, including alerts for critical high or critical low readings. Through the app, meter users can also share with their healthcare professional the reports of their blood glucose results and patterns, either in advance or on the day of their appointment, helping to create more informed discussions.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7954951-contour-next-one-bgms-ascensia/
As millions of Americans begin choosing a health plan for the first time under the Affordable Care Act, the new Healthgrades American Hospital Quality Outcomes 2014: Report to the Nation released today reveals how hospital selection can dramatically impact a patient’s health. The report demonstrates that individuals are far more likely to die or suffer complications at hospitals receiving the lowest Healthgrades rating. In fact, each year an estimated 234,252 lives could potentially be saved and 157,418 complications could be avoided if all hospitals performed similarly to the highest rated hospitals.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63942-healthgrades-american-hospital-quality-outcomes-2014-report-to-the-nation
BloodCenter of Wisconsin’s Diagnostic Laboratories, part of Versiti, today announced the launch of seven hematology genetics test panels. The new test panels enhance and expand BloodCenter’s genetic testing capability to include a vast array of non-malignant hematology disorders, including platelet function disorders, inherited thrombocytopenia and congenital neutropenias, providing one of the most comprehensive test menus in hematology.
BloodCenter’s integration of functional and genetic testing provides a unique approach to diagnosing complex hematology disorders, providing a comprehensive review of each patient for improved patient care and outcomes.
To view the multimedia release go to:
https://www.multivu.com/players/English/8126851-bloodcenter-of-wisconsin-versiti-hematology-genetics-test-panels/
Research shows that patients who don’t consistently follow their regular medication regimen are at risk for death or hospitalization. During American Pharmacists Month in October, American Pharmacists Association (APhA) Foundation is launching the Align My Refills campaign to help patients and caregivers maintain their medication regimen with patient resources and the aid of their local pharmacist.
To view Multimedia News Release, go to: http://www.multivu.com/players/English/7337851-american-pharmacists-association-foundation-align-my-refills-campaign/
Outsource dermatology transcription to reliable medical transcription services for precise, efficient documentation and delivery of quality patient care.
